BACKGROUND: High pulmonary vascular resistance (PVR) may be a risk factor for early and late mortality in both Glen shunt and Fontan operation patients. Furthermore, PVR may increase long after the Fontan operation. Whether pulmonary vasodilators such as phosphodiesterase 5 inhibitors can decrease PVR in patients with single ventricular physiology remains undetermined. METHODS AND RESULTS: This was a prospective, multicenter study. Patients with single ventricular physiology who have a PVR index higher than 2.5 Wood units·㎡ (WU) were enrolled. Cardiac catheterization was performed before and after administration of sildenafil in all patients. After the Fontan operation, a six minute walk test (6MWT) was also performed. A total of 42 patients were enrolled. PVR was significantly decreased in each stage of single ventricular physiology after sildenafil administration: from 4.3±1.5WU to 2.1±0.6WU (p<0.01) in patients before a Glenn shunt, from 3.2±0.5WU to 1.6±0.6WU (p<0.001) in patients after a Glenn shunt, and from 3.9±1.7WU to 2.3±0.8WU (p<0.001) in patients after Fontan. In patients after Fontan, the 6MWT increased from 416±74m to 485±72m (p<0.01), and NYHA functional class improved significantly (p<0.05) after sildenafil administration. No major side effects were observed in any patients. CONCLUSIONS: Sildenafil reduced PVR in patients with single ventricle physiology. Sildenafil increased exercise capacity and improved NYHA functional class in patients after a Fontan operation. This implies that pulmonary vasodilation is a potential therapeutic target in selected patients with elevated PVR with single ventricle physiology. Long-term clinical significance warrants further study.
BACKGROUND: High pulmonary vascular resistance (PVR) may be a risk factor for early and late mortality in both Glen shunt and Fontan operation patients. Furthermore, PVR may increase long after the Fontan operation. Whether pulmonary vasodilators such as phosphodiesterase 5 inhibitors can decrease PVR in patients with single ventricular physiology remains undetermined. METHODS AND RESULTS: This was a prospective, multicenter study. Patients with single ventricular physiology who have a PVR index higher than 2.5 Wood units·㎡ (WU) were enrolled. Cardiac catheterization was performed before and after administration of sildenafil in all patients. After the Fontan operation, a six minute walk test (6MWT) was also performed. A total of 42 patients were enrolled. PVR was significantly decreased in each stage of single ventricular physiology after sildenafil administration: from 4.3±1.5WU to 2.1±0.6WU (p<0.01) in patients before a Glenn shunt, from 3.2±0.5WU to 1.6±0.6WU (p<0.001) in patients after a Glenn shunt, and from 3.9±1.7WU to 2.3±0.8WU (p<0.001) in patients after Fontan. In patients after Fontan, the 6MWT increased from 416±74m to 485±72m (p<0.01), and NYHA functional class improved significantly (p<0.05) after sildenafil administration. No major side effects were observed in any patients. CONCLUSIONS:Sildenafil reduced PVR in patients with single ventricle physiology. Sildenafil increased exercise capacity and improved NYHA functional class in patients after a Fontan operation. This implies that pulmonary vasodilation is a potential therapeutic target in selected patients with elevated PVR with single ventricle physiology. Long-term clinical significance warrants further study.
Authors: David J Goldberg; Victor Zak; Bryan H Goldstein; Brian W McCrindle; Shaji C Menon; Kurt R Schumacher; R Mark Payne; Jonathan Rhodes; Kimberly E McHugh; Daniel J Penny; Felicia Trachtenberg; Michelle S Hamstra; Marc E Richmond; Peter C Frommelt; Matthew D Files; James L Yeager; Victoria L Pemberton; Mario P Stylianou; Gail D Pearson; Stephen M Paridon Journal: Am Heart J Date: 2018-04-03 Impact factor: 4.749
Authors: David J Goldberg; Victor Zak; Bryan H Goldstein; Kurt R Schumacher; Jonathan Rhodes; Daniel J Penny; Christopher J Petit; Salil Ginde; Shaji C Menon; Seong-Ho Kim; Gi Beom Kim; Todd T Nowlen; Michael V DiMaria; Benjamin P Frischhertz; Jonathan B Wagner; Kimberly E McHugh; Brian W McCrindle; Amanda J Shillingford; Arash A Sabati; Anji T Yetman; Anitha S John; Marc E Richmond; Matthew D Files; R Mark Payne; Andrew S Mackie; Christopher K Davis; Shabana Shahanavaz; Kevin D Hill; Ruchira Garg; Jeffrey P Jacobs; Michelle S Hamstra; Stacy Woyciechowski; Kathleen A Rathge; Michael G McBride; Peter C Frommelt; Mark W Russell; Elaine M Urbina; James L Yeager; Victoria L Pemberton; Mario P Stylianou; Gail D Pearson; Stephen M Paridon Journal: Circulation Date: 2019-11-17 Impact factor: 29.690
Authors: J Leslie Gaddis Collins; Mark A Law; Santiago Borasino; W Clinton Erwin; David C Cleveland; Jeffrey A Alten Journal: Pediatr Cardiol Date: 2017-09-07 Impact factor: 1.655
Authors: Alexander C Egbe; Heidi M Connolly; William R Miranda; Naser M Ammash; Donald J Hagler; Gruschen R Veldtman; Barry A Borlaug Journal: Circ Heart Fail Date: 2017-12 Impact factor: 8.790
Authors: Alexander C Egbe; Yogesh N V Reddy; Arooj R Khan; Mohamad Al-Otaibi; Emmanuel Akintoye; Masaru Obokata; Barry A Borlaug Journal: Int J Cardiol Date: 2018-11-15 Impact factor: 4.164
Authors: Coline Nydegger; Antonio F Corno; Ludwig K von Segesser; Maurice Beghetti; Michele Samaja; Giuseppina Milano Journal: Cardiovasc Drugs Ther Date: 2019-08 Impact factor: 3.727